Intracameral antibiotics: Safety, efficacy, and preparation

Journal of Cataract and Refractive Surgery

Volumn 40, Issue 12, 2014, Pages 2134-2142

  Braga Mele, Rosa ^a   Chang, David F ^b   Henderson, Bonnie An ^c   Mamalis, Nick ^d   Talley Rostov, Audrey ^e   Vasavada, Abhay ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Eye Associates Northwest   (United States)

^f Raghudeep Eye Clinic   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; OXACILLIN; QUINOLONE DERIVATIVE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTERIOR EYE SEGMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BORRELIA BURGDORFERI; CATARACT EXTRACTION; CITROBACTER; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; ENDOPHTHALMITIS; ENTEROBACTER; ESCHERICHIA COLI; EYE TOXICITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION PREVENTION; KLEBSIELLA; LEGIONELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; NEISSERIA GONORRHOEAE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PEPTOCOCCUS; PRIORITY JOURNAL; PROTEUS MIRABILIS; RETINA BLOOD VESSEL OCCLUSION; RETINA MACULA CYSTOID EDEMA; SALMONELLA; SHIGELLA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; TOXIC ANTERIOR SEGMENT SYNDROME;

EID: 84964297311     PISSN: 08863350     EISSN: 18734502     Source Type: Journal    
DOI: 10.1016/j.jcrs.2014.10.010     Document Type: Review

References (80)

1. M. Packer, D.F. Chang, S.H. Dewey, B.C. Little, N. Mamalis, T.A. Oetting, A. Talley-Rostov, S.H. Yoo for the ASCRS Cataract Clinical Committee Prevention, diagnosis and management of acute postoperative bacterial endophthalmitis J Cataract Refract Surg 37 2011 1699 1714
2. J.J. Miller, I.U. Scott, H.W. Flynn Jr., W.E. Smiddy, J. Newton, and D. Miller Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual outcomes after treatment Am J Ophthalmol 139 2005 983 987
3. ESCRS Endophthalmitis Study Group Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors J Cataract Refract Surg 33 2007 978 988
4. N.H. Shorstein, K.L. Winthrop, and L.J. Herrinton Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department J Cataract Refract Surg 39 2013 8 14
5. C.S.H. Tan, H.K. Wong, and F.P. Yang Epidemiology of postoperative endophthalmitis in an Asian population: 11-year incidence and effect of intracameral antibiotic agents J Cataract Refract Surg 38 2012 425 430
6. P.G. Montan, G. Wedje, G. Koranyi, and M. Rylander Prophylactic intracameral cefuroxime; efficacy in preventing endophthalmitis after cataract surgery J Cataract Refract Surg 28 2002 977 981
7. M.C. García-Sáenz, A. Arias-Puente, G. Rodríguez-Caravaca, and J.B. Bañuelos Effectiveness of intracameral cefuroxime in preventing endophthalmitis after cataract surgery; ten-year comparative study J Cataract Refract Surg 36 2010 203 207
8. H.V. Gimbel, R. Sun, and B.M. de Brof Prophylactic intracameral antibiotics during cataract surgery: the incidence of endophthalmitis and corneal endothelial cell loss Eur J Implant Refract Surg 6 1994 280 285
9. C.R.G. Espiritu, V.L. Caparas, and J.G. Bolinao Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients J Cataract Refract Surg 33 2007 63 68
10. S.S. Lane, R.H. Osher, S. Masket, and S. Belani Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery J Cataract Refract Surg 34 2008 1451 1459
11. L.B. Arbisser Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery J Cataract Refract Surg 34 2008 1114 1120
12. E. Yoeruek, M.S. Spitzer, O. Saygili, O. Tatar, T. Biedermann, E. Yoeruek, K.U. Bartz-Schmidt, and P. Szurman Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use J Cataract Refract Surg 34 2008 2139 2145
13. M. Hui, P.T.H. Lam, S.-W. Cheung, C.-P. Pang, C.-Y. Chan, and D.S.C. Lam In vitro compatibility study of cephalosporin with intraocular irrigating solutions and intracameral medications Clin Experiment Ophthalmol 39 2011 164 170
14. P.A. Asbell, K.A. Colby, S. Deng, P. McDonnell, D.M. Meisler, M.B. Reizman, J.D. Sheppard Jr., and D.F. Sahm Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates Am J Ophthalmol 145 2008 951 958
15. J.F. Ferro, M. de-Pablos, M.J. Logroño, L. Guisasola, and F. Aizpuru Postoperative contamination after using vancomycin and gentamicin during phacoemulsification Arch Ophthalmol 115 1997 165 170
16. S.C. Pflugfelder, E. Hernández, S.J. Fliesler, J. Alvarez, M.E. Pflugfelder, and R.K. Forster Intravitreal vancomycin: retinal toxicity, clearance, and interaction with gentamicin Arch Ophthalmol 105 1987 831 837
17. P.E. Libre, P. Della-Latta, and N.-X. Chin Intracameral antibiotic agents for endophthalmitis prophylaxis: a pharmacokinetic model J Cataract Refract Surg 29 2003 1791 1794
18. L. Kodjikian, C. Burillon, and J.G. Garweg Intracameral vancomycin and endophthalmitis prophylaxis [letter] J Cataract Refract Surg 30 2004 2030 reply by PE Libre, 2030-2031
19. Endophthalmitis Vitrectomy Study Group Results of the Endophthalmitis Vitrectomy Study; a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis Arch Ophthalmol 113 1995 1479 1496
20. T.M. Aaberg Jr., H.W. Flynn Jr., J. Schiffman, and J. Newton Nosocomial acute-onset postoperative endophthalmitis survey; a 10- year review of incidence and outcomes Ophthalmology 105 1998 1004 1010
21. N. Morlet, J. Li, J. Semmens, and J. Ng The Endophthalmitis Population Study of Western Australia (EPSWA): first report; on behalf of teamEPSWA Br J Ophthalmol 87 2003 574 576 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771660/pdf/bjo08700574.pdf Accessed August 20, 2014
22. N. Mamalis, L. Kearsley, and E. Brinton Postoperative endophthalmitis Curr Opin Ophthalmol 13 2002 14 18
23. D.Y. Kunimoto, T. Das, S. Sharma, S. Jalali, A.B. Majji, U. Gopinathan, S. Athmanathan, T.N. Rao the Endophthalmitis Research Group Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis Am J Ophthalmol 128 1999 240 242
24. P.J.M. Bispo, E.C. Alfonso, H.W. Flynn, and D. Miller Emerging 8-methoxyfluoroquinolone resistance among methicillin-susceptible Staphylococcus epidermidis isolates recovered from patients with endophthalmitis J Clin Microbiol 51 2013 2959 2965 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754617/pdf/zjm2959.pdf Accessed August 20, 2014
25. ®): a novel fluoroquinolone with a broad spectrum of activity Expert Rev Anti Infect Ther 1 2003 363 370
26. J.A. Barman Balfour, and H.M. Lamb Moxifloxacin; a review of its clinical potential in the management of community-acquired respiratory tract infections Drugs 59 2000 115 139
27. D.A. Talan Clinical perspectives on new antimicrobials: focus on fluoroquinolones Clin Infect Dis 32 suppl 1 2001 S64 S71 Available at: http://cid.oxfordjournals.org/content/32/Supplement-1/S64.full.pdf Accessed August 20, 2014
28. L. Asena, Y.A. Akova, M.T. Goktaş, A. Bozkurt, Ü. Yaşar, G. Karabay, and E. Dermiralay Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model Curr Eye Res 38 2013 472 479
29. ®) Surv Ophthalmol 50 suppl 1 2005 S7 S15
30. R. Mather, L.M. Karenchak, E.G. Romanowski, and R.P. Kowalski Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics Am J Ophthalmol 133 2002 463 466
31. ® (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model Am J Ophthalmol 140 2005 497 504
32. F.S. Mah Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections Curr Opin Ophthalmol 15 2004 316 320
33. H.C. Neu, and K.P. Fu Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity Antimicrob Agents Chemother 13 1978 657 664 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC352306/pdf/aac00286-0109.pdf Accessed August 20, 2014
34. C.M. Petty, and R.N. Brogden Cefuroxime axetil; a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy Drugs 52 1996 125 158
35. ®): a brief review Infect Dis Obstet Gynecol 5 1997 211 214 Available at: http://downloads.hindawi.com/journals/idog/1997/909343.pdf Accessed August 20, 2014
36. J.E. Geraci Vancomycin Mayo Clin Proc 52 1977 631 634
37. S. Deresinski Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 49 2009 1072 1079 Available at: http://cid.oxfordjournals.org/content/49/7/1072.full.pdf Accessed August 20, 2014
38. A.M. Schimel, D. Miller, and H.W. Flynn Jr. Endophthalmitis isolates and antibiotic susceptibilities: a 10-year review of culture-proven cases Am J Ophthalmol 156 2013 50 52
39. T.P. O'Brien, S.A. Arshinoff, and F.S. Mah Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin J Cataract Refract Surg 33 2007 1790 1800
40. C.C. Murphy, S. Nicholson, S.A. Quah, M. Batterbury, T. Neal, and S.B. Kaye Pharmacokinetics of vancomycin following intracameral bolus injection in patients undergoing phacoemulsification cataract surgery Br J Ophthalmol 91 2007 1350 1353 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001025/pdf/1350.pdf Accessed August 20, 2014
41. S.K. Gardner Ocular drug penetration and pharmacokinetic principles D.W. Lamberts, D.E. Potter, Clinical Ophthalmic Pharmacology 1987 Little, Brown and Company Boston, MA 1 52
42. J.P. McCulley, D. Caudle, J.D. Aronowicz, and W.E. Shine Fourth-generation fluoroquinolone penetration into the aqueous humor in humans Ophthalmology 113 2006 955 959
43. R. Solomon, E.D. Donnenfeld, H.D. Perry, R.W. Snyder, C. Nedrud, J. Stein, and A. Bloom Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor Ophthalmology 112 2005 466 469
44. L. Ong-Tone Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery J Cataract Refract Surg 33 2007 59 62
45. H.R. Katz, S. Masket, S.S. Lane, K. Sall, S.C. Orr, R.D. Faulkner, B.A. McCue, and D.C. Dahlin Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor Cornea 24 2005 955 958
46. D.H. Kim, W.J. Stark, T.P. O'Brien, and J.D. Dick Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients Ophthalmology 112 2005 1992 1996
47. S.M. Hariprasad, K.J. Blinder, G.K. Shah, R.S. Apte, B. Rosenblatt, N.M. Holekamp, M.A. Thomas, W.F. Mieler, J. Chi, and R.A. Prince Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous Arch Ophthalmol 123 2005 39 44 Available at: http://archopht.jamanetwork.com/data/Journals/OPHTH/9934/ECS40010.pdf Accessed August 20, 2014
48. W.W. Lai, K.O. Chu, K.P. Chan, K.W. Choy, C.C. Wang, C.W. Tsang, and C.P. Pang Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy Am J Ophthalmol 144 2007 315 318
49. G. Wejde, P. Montan, M. Lundström, U. Stenevi, and W. Thorburn Endophthalmitis following cataract surgery in Sweden: national prospective survey 1999-2001 Acta Ophthalmol Scand 83 2005 7 10 Available at: http://www3.interscience.wiley.com/cgi-bin/fulltext/120092610/PDFSTART Accessed August 20, 2014
50. M. Lundström, G. Wejde, U. Stenevi, W. Thorburn, and P. Montan Endophthalmitis after cataract surgery; a nationwide prospective study evaluating incidence in relation to incision type and location Ophthalmology 114 2007 866 870
51. E. Friling, M. Lundström, U. Stenevi, and P. Montan Six-year incidence of endophthalmitis after cataract surgery: Swedish national study J Cataract Refract Surg 39 2013 15 21
52. G. Rodríguez-Caravaca, M.C. García-Sáenz, M.C. Villar-del-Campo, Y. Andrés-Alba, and A. Arias-Puente Incidence of endophthalmitis and impact of prophylaxis with cefuroxime on cataract surgery J Cataract Refract Surg 39 2013 1399 1403
53. M. Garat, C.L. Moser, C. Alonso-Tarrés, M. Martín-Baranera, and A. Alberdi Intracameral cefazolin to prevent endophthalmitis in cataract surgery: 3-year retrospective study J Cataract Refract Surg 31 2005 2230 2234
54. P. Romero, I. Méndez, M. Salvat, J. Fernández, and M. Almena Intracameral cefazolin as prophylaxis against endophthalmitis in cataract surgery J Cataract Refract Surg 32 2006 438 441
55. P. Yu-Wai-Man, S.J. Morgan, A.J. Hildreth, D.H. Steel, and D. Allen Efficacy of intracameral and subconjunctival cefuroxime in preventing endophthalmitis after cataract surgery J Cataract Refract Surg 34 2008 447 451
56. G. Barreau, M. Mounier, B. Marin, J.-P. Adenis, and P.-Y. Robert Intracameral cefuroxime injection at the end of cataract surgery to reduce the incidence of endophthalmitis: French study J Cataract Refract Surg 38 2012 1370 1375
57. A. Mendívil, and M.P. Mendívil The effect of topical povidone-iodine, intraocular vancomycin, or both on aqueous humor cultures at the time of cataract surgery Am J Ophthalmol 131 2000 293 300
58. M.J. Rybak, E.M. Bailey, K.C. Lamp, and G.W. Kaatz Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia Antimicrob Agents Chemother 36 1992 1109 1114 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC188844/pdf/aac00039-0237.pdf Accessed August 20, 2014
59. Y.J. Gordon Vancomycin prophylaxis and emerging resistance: are ophthalmologists the villains? The heroes? Am J Ophthalmol 131 2001 371 376
60. T. Harper, D. Miller, and H.W. Flynn Jr. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates Ophthalmology 114 2007 871 875
61. J. Freidlin, N. Acharya, T.M. Lietman, V. Cevallos, J.P. Whitcher, and T.P. Margolis Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus Am J Ophthalmol 144 2007 313 315
62. J.C. Major Jr., M. Engelbert, H.W. Flynn Jr., D. Miller, W.E. Smiddy, and J.L. Davis Staphylococcus aureus endophthalmitis: antibiotic susceptibilities, methicillin resistance, and clinical outcomes Am J Ophthalmol 149 2010 278 283
63. N. Mamalis, H.F. Edelhauser, D.G. Dawson, J. Chew, R.M. LeBoyer, and L. Werner Toxic anterior segment syndrome J Cataract Refract Surg 32 2006 324 333
64. N. Mamalis Intracameral medication: is it worth the risk? [editorial] J Cataract Refract Surg 34 2008 339 340
65. M.-N. Delyfer, M.-B. Rougier, S. Leoni, Q. Zhang, F. Dalbon, J. Colin, and J.-F. Korobelnik Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery J Cataract Refract Surg 37 2011 271 278
66. F. Qureshi, and D. Clark Macular infarction after inadvertent intracameral cefuroxime J Cataract Refract Surg 37 2011 1168 1169
67. S. Çiftçi, L. Çiftçi, and U. Daʇ Hemorrhagic retinal infarction due to inadvertent overdose of cefuroxime in cases of complicated cataract surgery: retrospective case series Am J Ophthalmol 157 2014 421 425
68. D. Lockington, H. Flowers, D. Young, and D. Yorston Assessing the accuracy of intracameral antibiotic preparation for use in cataract surgery J Cataract Refract Surg 36 2010 286 289
69. M. Blumenthal Prophylactic intracameral vancomycin and CME [letter] Ophthalmology 107 2000 1616 1617 reply by R Axer-Siegel, 1617
70. M.S. Gupta, H.D.R. McKee, M. Saldaña, and O.G. Stewart Macular thickness after cataract surgery with intracameral cefuroxime J Cataract Refract Surg 31 2005 1163 1166
71. M.K. Jensen, R.G. Fiscella, A.S. Crandall, M. Moshirfar, B. Mooney, T. Wallin, and R.J. Olson A retrospective study of endophthalmitis rates comparing quinolone antibiotics Am J Ophthalmol 139 2005 141 148
72. J. Shahar, E. Zemel, I. Perlman, and A. Loewenstein Physiological and toxicological effects of cefuroxime on the albino rabbit retina Invest Ophthalmol Vis Sci 53 2012 906 914 Available at: http://www.iovs.org/content/53/2/906.full.pdf Accessed August 20, 2014
73. E. Moisseiev, and E. Levinger Anaphylactic reaction following intracameral cefuroxime injection during cataract surgery J Cataract Refract Surg 39 2013 1432 1434
74. J.R. Villada, U. Vicente, J. Javaloy, and J.L. Alió Severe anaphylactic reaction after intracameral antibiotic administration during cataract surgery J Cataract Refract Surg 31 2005 620 621
75. E. Sharifi, T.C. Porco, and A. Naseri Cost-effectiveness analysis of intracameral cefuroxime use for prophylaxis of endophthalmitis after cataract surgery Ophthalmology 116 2009 1887 1896
76. D.F. Chang, R. Braga-Mele, N. Mamalis, S. Masket, K.M. Miller, L.D. Nichamin, R.B. Packard, M. Packer for the ASCRS Cataract Clinical Committee Prophylaxis of postoperative endophthalmitis after cataract surgery; results of the 2007 ASCRS member survey J Cataract Refract Surg 33 2007 1801 1805
77. Itokazu G. Cephalosporins. Course given at the University of Illinois at Chicago, Chicago, IL. Available at: http://www.uic.edu/pharmacy/courses/pmpr342/itokazu/cephalosporins.html. Accessed August 20, 2014
78. Vancomycin dosing. Plattsburg, MO, RxKinetics. Available at: http://www.rxkinetics.com/vanco.html. Accessed August 20, 2014
79. Nick Mamalis, MD, personal communication, June 5, 2014
80. Mamalis N, ASCRS Alert: TASS associated with intracameral antibiotic injection. ASCRS This Week, May 8, 2013